Utama › Dermatitis Atopik (Eksim) › Pennsylvania
Kajian klinikal Dermatitis Atopik (Eksim) di Pennsylvania
13 kajian untuk Dermatitis Atopik (Eksim) sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- UPMC - Department of Dermatology- Site Number : 8400024, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Camp Hill
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07298395A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Paddington Testing Co, Inc, Philadelphia
- UPMC Department of Dermatology, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 hingga 64 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07216027A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07003425A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Best Skin Research LLC, Camp Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Best Skin Research, LLC, Camp Hill
- UPMC Department of Dermatology, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07599813FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Paddington Testing Company, Philadelphia
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 70 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06564389A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Research of Philadelphia /ID# 264972, Philadelphia
- University of Pittsburgh Medical Center /ID# 264526, Pittsburgh
- Dermatology Associates of Plymouth Meeting /ID# 267286, Plymouth Meeting
Mengambil pesertaFasa 3
Umur 18 hingga 63 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06389136The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
- University of Pittsburgh Medical Center, Pittsburgh
- UPMC Department of Dermatology, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT06928246A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Paddington Testing Co, Inc, Philadelphia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8559, Philadelphia
- Galderma Investigational Site 7103, Philadelphia
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT06988605Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- University of Pittsburgh Medical Center, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Dis 2025 · NCT00177268A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- DermDox Centers for Dermatology, Camp Hill
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Sep 2025 · NCT06055361Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.